DDD Partners LLC Invests $5.97 Million in Elanco Animal Health Incorporated (NYSE:ELAN)

DDD Partners LLC bought a new position in shares of Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 493,276 shares of the company's stock, valued at approximately $5,974,000. DDD Partners LLC owned 0.10% of Elanco Animal Health as of its most recent SEC filing.

A number of other large investors have also recently added to or reduced their stakes in ELAN. Rhumbline Advisers boosted its position in shares of Elanco Animal Health by 0.5% in the fourth quarter. Rhumbline Advisers now owns 481,438 shares of the company's stock valued at $5,830,000 after acquiring an additional 2,209 shares during the period. Blue Trust Inc. boosted its position in shares of Elanco Animal Health by 47.7% in the fourth quarter. Blue Trust Inc. now owns 5,862 shares of the company's stock valued at $71,000 after acquiring an additional 1,894 shares during the period. MTM Investment Management LLC boosted its position in shares of Elanco Animal Health by 9.3% in the fourth quarter. MTM Investment Management LLC now owns 14,168 shares of the company's stock valued at $172,000 after acquiring an additional 1,200 shares during the period. Van ECK Associates Corp boosted its position in shares of Elanco Animal Health by 4.0% in the fourth quarter. Van ECK Associates Corp now owns 944,978 shares of the company's stock valued at $11,444,000 after acquiring an additional 36,239 shares during the period. Finally, Summit Trail Advisors LLC bought a new stake in shares of Elanco Animal Health in the fourth quarter valued at approximately $199,000. Institutional investors own 97.48% of the company's stock.

Elanco Animal Health Price Performance

Elanco Animal Health stock traded down $0.10 during mid-day trading on Thursday, hitting $11.15. 2,710,579 shares of the company were exchanged, compared to its average volume of 4,506,272. The company has a quick ratio of 1.31, a current ratio of 2.55 and a debt-to-equity ratio of 0.66. The business has a fifty day moving average of $11.83 and a 200 day moving average of $13.10. Elanco Animal Health Incorporated has a 1-year low of $10.77 and a 1-year high of $18.80. The company has a market capitalization of $5.51 billion, a PE ratio of 27.86, a price-to-earnings-growth ratio of 2.55 and a beta of 1.42.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on the company. Leerink Partnrs raised Elanco Animal Health to a "hold" rating in a research report on Monday, December 2nd. Leerink Partners assumed coverage on Elanco Animal Health in a research report on Monday, December 2nd. They issued a "market perform" rating and a $14.00 price objective for the company. Morgan Stanley cut their target price on Elanco Animal Health from $15.00 to $14.00 and set an "equal weight" rating for the company in a research note on Wednesday, January 29th. UBS Group assumed coverage on Elanco Animal Health in a research note on Monday, December 9th. They issued a "buy" rating and a $18.00 target price for the company. Finally, Barclays upped their target price on Elanco Animal Health from $19.00 to $20.00 and gave the company an "overweight" rating in a research note on Friday, November 8th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and three have issued a buy rating to the company. According to data from MarketBeat, Elanco Animal Health has a consensus rating of "Hold" and a consensus target price of $16.29.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.